Cover Page
Document Information [Table]
Document Information [Line Items]
Document Type
Document Type
Document Quarterly Report
Document Quarterly Report
Document Period End Date
Document Period End Date
Document Fiscal Year Focus
Document Fiscal Year Focus
Document Transition Report
Document Transition Report
Securities Act File Number
Entity File Number
Entity Registrant Name
Entity Registrant Name
Entity Incorporation, State or Country Code
Entity Incorporation, State or Country Code
Entity Tax Identification Number
Entity Tax Identification Number
Entity Address, Address Line One
Entity Address, Address Line One
Entity Address, City or Town
Entity Address, City or Town
Entity Address, State or Province
Entity Address, State or Province
Entity Address, Postal Zip Code
Entity Address, Postal Zip Code
City Area Code
City Area Code
Local Phone Number
Local Phone Number
Title of 12(b) Security
Title of 12(b) Security
Trading Symbol
Trading Symbol
Security Exchange Name
Security Exchange Name
Entity Current Reporting Status
Entity Current Reporting Status
Entity Interactive Data Current
Entity Interactive Data Current
Entity Filer Category
Entity Filer Category
Entity Small Business
Entity Small Business
Entity Emerging Growth Company
Entity Emerging Growth Company
Entity Shell Company
Entity Shell Company
Entity Common Stock, Shares Outstanding
Entity Common Stock, Shares Outstanding
Entity Central Index Key
Entity Central Index Key
Current Fiscal Year End Date
Current Fiscal Year End Date
Document Fiscal Period Focus
Document Fiscal Period Focus
Amendment Flag
Amendment Flag
Condensed Consolidated Balance Sheets
Assets [Abstract]
ASSETS
Assets, Current [Abstract]
CURRENT ASSETS:
Cash and Cash Equivalents, at Carrying Value
Cash and cash equivalents
Marketable Securities, Current
Marketable securities
Accounts Receivable, after Allowance for Credit Loss, Current
Accounts receivable, net
Inventory, Net
Inventory
Prepaid Expense and Other Assets, Current
Prepaid expenses and other current assets
Assets, Current
Total current assets
Property, Plant and Equipment, Net
Property and equipment, net
Total Property and equipment, net
Operating Lease, Right-of-Use Asset
Right-of-use assets
Equity Securities without Readily Determinable Fair Value, Amount
Strategic investments
Strategic investments
Represents the value of deposits and other assets.
Deposits And Other Assets
Deposits and other assets
Assets
TOTAL ASSETS
Liabilities and Equity [Abstract]
LIABILITIES, SERIES A PREFERRED STOCK AND STOCKHOLDERS' EQUITY
Liabilities, Current [Abstract]
CURRENT LIABILITIES:
Accounts Payable, Current
Accounts payable
Accrued Liabilities, Current
Accrued expenses and other liabilities
Total Accrued expenses and other liabilities
Operating Lease, Liability, Current
Operating lease liability, current portion
Liabilities, Current
Total current liabilities
This amount of contractual agreement where an investor pays upfront to receive a share of future revenues. It defines the terms of the purchase, including the products involved, payment structure, and rights of the investor.
Revenue Interest Purchase Agreement Liability
Ending balance
Beginning balance
Royalty purchase agreement
Loans Payable, Noncurrent
Loan payable
Embedded Derivative, Fair Value of Embedded Derivative Liability
Derivative liability, ending balance
Derivative liability, beginning balance
Derivative liability
Operating Lease, Liability, Noncurrent
Operating lease liability, less current portion
Other Liabilities, Noncurrent
Other long-term liabilities
Liabilities
TOTAL LIABILITIES
Temporary Equity, Including Noncontrolling Interest
Ending balance
Beginning balance
Series A Preferred Stock, $0.0001 par value per share; 200,000 issued and outstanding at March 31, 2026 and December 31, 2025; aggregate liquidation preference of $20,000
Equity, Attributable to Parent [Abstract]
STOCKHOLDERS' EQUITY
Preferred Stock, Value, Issued
Preferred stock, $0.0001 par value, 10,000,000 shares authorized;
Common Stock, Value, Issued
Common stock, $0.0001 par value per share; 340,000,000 shares authorized; 58,630,715 and 57,032,963 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively.
Additional Paid in Capital
Additional paid-in capital
Accumulated Other Comprehensive Income (Loss), Net of Tax
Accumulated other comprehensive (loss) income
Retained Earnings (Accumulated Deficit)
Accumulated deficit
Equity, Including Portion Attributable to Noncontrolling Interest
Balance
Balance
TOTAL STOCKHOLDERS' EQUITY
Liabilities and Equity
TOTAL LIABILITIES, SERIES A PREFERRED STOCK AND STOCKHOLDERS' EQUITY
Temporary Equity, Par or Stated Value Per Share
Series A redeemable preferred stock, par value (in dollars per share)
Temporary Equity, Shares Issued
Series A redeemable preferred stock, shares issued
Temporary Equity, Shares Outstanding
Series A redeemable preferred stock, shares outstanding
Temporary Equity, Liquidation Preference
Series A redeemable preferred stock, liquidation preference
Preferred Stock, Par or Stated Value Per Share
Preference shares, par value (in Dollars per share)
Preferred stock, par value (in dollars per share)
Preferred Stock, Shares Authorized
Preference shares, shares authorized
Preferred stock, shares authorized
Common Stock, Par or Stated Value Per Share
Common stock, par value (in dollars per share)
Common Stock, Shares Authorized
Common stock, shares authorized
Common Stock, Shares, Issued
Common stock, shares issued
Common Stock, Shares, Outstanding
Common stock, shares outstanding
Condensed Consolidated Statements of Operations and Comprehensive Loss
Statement [Table]
Product and Service [Axis]
Product and Service [Domain]
n/a.
Partnership Revenue Member
Partnership revenue
Product [Member]
Product revenue
Statement [Line Items]
Revenues [Abstract]
Revenue:
Revenues
Total revenue
Operating Expenses [Abstract]
Expenses:
Cost of Revenue
Cost of product revenues
Research and Development Expense
Research and development
Selling, General and Administrative Expense
Selling, general and administrative
Costs and Expenses
Total expenses
Operating Income (Loss)
Loss from operations
Nonoperating Income (Expense) [Abstract]
Other (expense) income:
Interest Income (Expense), Nonoperating
Interest expense (income), net
Interest (expense) income, net
Embedded Derivative, Gain (Loss) on Embedded Derivative, Net
Change in the fair value of derivative liability
Change in the fair value of derivative liability
Gain (Loss) on Sale of Investments
Gain on sale of strategic investments
Gain on sale of strategic investments
Other Operating Income (Expense), Net
Total other income
Net loss
Net loss
Temporary Equity, Accretion to Redemption Value, Adjustment
Adjustment to carrying value of Series A Preferred Stock
Net Income (Loss) Available to Common Stockholders, Basic
Net loss attributable to common stockholders
Net Loss Per Share
Net loss attributable to common stockholders per share
Earnings Per Share, Basic
Basic (in dollars per share)
Earnings Per Share, Diluted
Diluted (in dollars per share)
Weighted Average Number of Shares Outstanding, Basic
Weighted-average shares used in computing net loss attributable to common stockholders per share, basic (in shares)
Weighted Average Number of Shares Outstanding, Diluted
Weighted-average shares used in computing net loss attributable to common stockholders per share, diluted (in shares)
Comprehensive Loss Abstract
Comprehensive loss
Marketable Security, Unrealized Gain (Loss)
Unrealized loss on marketable securities
Unrealized loss on marketable securities
Comprehensive Income (Loss), Net of Tax, Attributable to Parent
Comprehensive loss
Condensed Consolidated Statements of Stockholders' Equity
Equity Components [Axis]
Equity Component [Domain]
Common Stock [Member]
Common Stock
Additional Paid-in Capital [Member]
Additional Paid-in Capital
AOCI Attributable to Parent [Member]
Accumulated Other Comprehensive (Loss) Income
Retained Earnings [Member]
Accumulated Deficit
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Increase (Decrease) in Stockholders' Equity
Shares, Outstanding
Balance (in Shares)
Balance (in shares)
Stock Issued During Period, Value, New Issues
Aggregate purchase price
At-the-Market offering, net of issuance costs
Stock Issued During Period, Shares, New Issues
At-the-Market offering, net of issuance costs (in shares)
Shares issued (in shares)
APIC, Share-Based Payment Arrangement, Increase for Cost Recognition
Stock-based compensation
Value of stock related to vesting of Restricted Stock Awards during the period.
Stock Issued During Period, Value, Restricted Stock Award, Vesting
Restricted stock unit vesting
Number of shares related to vesting of Restricted Stock Award during the period.
Stock Issued During Period, Shares, Restricted Stock Award, Vesting
Restricted stock unit vesting (in shares)
Stock Issued During Period, Value, Stock Options Exercised
Exercise of stock options
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period
Shares Underlying Options, Exercised
Exercise of stock options (in shares)
Amount of increase (decrease) in Adjustment to carrying value of Series A Preferred Stock.
Increase Decrease In Adjustment to Carrying Value of Series A Preferred Stock
Adjustment to carrying value of Series A Preferred Stock
Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs
Offering costs
Condensed Consolidated Statements of Cash Flows
Net Cash Provided by (Used in) Operating Activities [Abstract]
CASH FLOWS FROM OPERATING ACTIVITIES:
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest
Net loss
Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation, Depletion and Amortization
Depreciation and amortization
Depreciation and amortization expense
Share-Based Payment Arrangement, Noncash Expense
Stock-based compensation
Amount of interest expense on liability related to Revenue Interest Purchase Agreement that result in no cash flow.
Non Cash Interest Expense on Liability Related to Revenue Interest Purchase Agreement
Non-cash interest expense on liability related to the royalty purchase agreement
Accretion (Amortization) of Discounts and Premiums, Investments
Accretion and interest related to marketable securities
Operating Lease, Right-of-Use Asset, Periodic Reduction
Non-cash lease expense
Amortization of Debt Issuance Costs
Amortization of deferred financing fees
Increase (Decrease) in Operating Capital [Abstract]
Changes in operating assets and liabilities:
Increase (Decrease) in Accounts Receivable
Accounts receivable
Increase (Decrease) in Inventories
Inventory
Increase (Decrease) in Prepaid Expense and Other Assets
Prepaid expenses and other assets
Increase (Decrease) in Accounts Payable and Accrued Liabilities
Accounts payable, accrued expenses and other liabilities
Increase (Decrease) in Operating Lease Liability
Operating lease liabilities - current and non-current
Increase (Decrease) in Contract with Customer, Liability
Deferred revenue
Net Cash Provided by (Used in) Operating Activities
Net cash used in operating activities
Net Cash Provided by (Used in) Investing Activities [Abstract]
CASH FLOWS FROM INVESTING ACTIVITIES:
Payments to Acquire Property, Plant, and Equipment
Purchases of property and equipment
Proceeds from Sale and Maturity of Marketable Securities
Sales of marketable securities
Payments to Acquire Marketable Securities
Purchases of marketable securities
Proceeds from Sale of Long-Term Investments
Sale of strategic investments
Net Cash Provided by (Used in) Investing Activities
Net cash provided by investing activities
Net Cash Provided by (Used in) Financing Activities [Abstract]
CASH FLOWS FROM FINANCING ACTIVITIES:
Sale of Stock, Consideration Received on Transaction
Net proceeds from common stock
Proceeds from At-The-Market offering, net of issuance costs
Proceeds from Stock Options Exercised
Proceeds from exercise of stock options
Payment, Tax Withholding, Share-Based Payment Arrangement
Restricted stock units withheld for tax
Net Cash Provided by (Used in) Financing Activities
Net cash provided by (used in) financing activities
Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect
Net decrease in cash and cash equivalents
Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents
Cash and cash equivalents, end of the period
Cash and cash equivalents, beginning of the period
Interest Paid, Including Capitalized Interest, Operating and Investing Activities [Abstract]
Cash paid during the three months ended March 31:
Interest Paid, Including Capitalized Interest, Operating and Investing Activities
Interest
Noncash Investing and Financing Items [Abstract]
Supplemental disclosure of noncash activities
Capital Expenditures Incurred but Not yet Paid
Purchases of Property & equipment within accounts payable, accrued expenses and other liabilities
Organization and Basis of Presentation
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]
Organization and Basis of Presentation
Summary of Significant Accounting Policies
Significant Accounting Policies [Text Block]
Summary of Significant Accounting Policies
Medtronic Agreement
Medtronic Agreement Text Block
Medtronic Agreement
Financial Instruments and Fair Value Measurements
Fair Value Disclosures [Text Block]
Financial Instruments and Fair Value Measurements
Marketable Securities and Strategic Investments
Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]
Marketable Securities and Strategic Investments
Balance Sheet Components
Supplemental Balance Sheet Disclosures [Text Block]
Balance Sheet Components
Common and Preferred Stock
Equity [Text Block]
Common and Preferred Stock
Derivative Liability
Derivative Instruments and Hedging Activities Disclosure [Text Block]
Derivative Liability
Warrants
Disclosure of warrants.
Warrants Disclosure Text Block
Warrants
Stock-Based Compensation
Share-Based Payment Arrangement [Text Block]
Stock-Based Compensation
Leases
Lessee, Operating Leases [Text Block]
Leases
Related Party Transactions
Related Party Transactions Disclosure [Text Block]
Related Party Transactions
N/A
Royalty Purchase Agreement
The entire disclosure for Royalty purchase agreement entered during the period.
Revenue Interest Purchase Agreement [Text Block]
Royalty Purchase Agreement
Debt Financing
Debt Disclosure [Text Block]
Debt Financing
Segment Disclosures
Segment Reporting Disclosure [Text Block]
Segment Disclosures
Earnings Per Share [Text Block]
Net Loss Per Share
Use of Estimates, Policy [Policy Text Block]
Use of Estimates
Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]
Cash and Cash Equivalents
Marketable Securities, Policy [Policy Text Block]
Marketable Securities
Investment, Policy [Policy Text Block]
Strategic Investments
Fair Value of Financial Instruments, Policy [Policy Text Block]
Fair Value of Financial Instruments
Accounts Receivable [Policy Text Block]
Accounts Receivable and Allowance for Doubtful Accounts
Inventory, Policy [Policy Text Block]
Inventory
Research and Development Expense, Policy [Policy Text Block]
Research and Development Prepayments, Accruals and Related Expenses
Property, Plant and Equipment, Policy [Policy Text Block]
Property and Equipment
Lessee, Leases [Policy Text Block]
Leases
Debt, Policy [Policy Text Block]
Debt Discount and Debt Issuance Costs
Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]
Impairment of Long-Lived Assets
Revenue from Contract with Customer [Policy Text Block]
Revenue Recognition
The entire disclosure of partnership revenue policy.
Partnership Revenue Policy Text Block
Partnership Revenues
The entire disclosure of product revenues policy.
Product Revenues Policy Text Block
Product Revenues
Share-Based Payment Arrangement [Policy Text Block]
Stock-Based Compensation
Stockholders' Equity Note, Redeemable Preferred Stock, Issue, Policy [Policy Text Block]
Series A Preferred Stock
Derivatives, Embedded Derivatives [Policy Text Block]
Derivative Liability
Earnings Per Share, Policy [Policy Text Block]
Net Loss Per Share
Income Tax, Policy [Policy Text Block]
Income Taxes
The entire disclosure of defined contribution plan policy.
Defined Contribution Plan Policy Text Block
Defined Contribution Plan
Comprehensive Income, Policy [Policy Text Block]
Comprehensive Loss
Segment Reporting, Policy [Policy Text Block]
Segment Reporting
New Accounting Pronouncements, Policy [Policy Text Block]
New Accounting Standards
Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale useful lives.
Property Plant And Equipment Useful Lives Table Text Block
Schedule of property and equipment useful lives
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]
Schedule of financial assets and liabilities measured at fair value
Marketable Securities [Table Text Block]
Schedule of marketable securities
Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets.
Property Plant And Equipment Balances Table Text Block
Schedule of property and equipment balances, net
Schedule of Accrued Liabilities [Table Text Block]
Schedule of accrued expenses and other liabilities
Temporary Equity [Table Text Block]
Schedule of roll-forward of the Series A Preferred Stock activity
Tabular disclosure of embedded derivative liability recognized at fair value.
Schedule Of Reconciliation Of Embedded Derivative Liabilities At Fair Value [Table Text Block]
Schedule of reconciliation of the derivative liability associated with the Series A Preferred Stock
Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for derivative liabilities measured on recurring and nonrecurring basis.
Fair Value Measurement Inputs And Valuation Techniques For Derivative Components [Table Text Block]
Schedule of assumptions to value the derivative components
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]
Schedule of purchase shares of Company Common Stock
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]
Schedule of cost related to stock-based compensation
Share-Based Payment Arrangement, Option, Activity [Table Text Block]
Schedule of stock option activity
Nonvested Restricted Stock Shares Activity [Table Text Block]
Schedule of restricted stock activity
Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]
Schedule of estimated grant-date fair value calculated using Black-Scholes option pricing model
Tabular disclosure of the operating leases supplemental information.
Schedule Of Operating Leases Supplemental Information Table Text Block
Schedule of recognized as an asset and operating lease liabilities
Lease, Cost [Table Text Block]
Schedule of lease expense
Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]
Schedule of future minimum rental payments, exclusive of taxes, insurance and other costs, under the leases
Tabular disclosure of activity of royalty purchase agreement liability.
Schedule of Activity of Revenue Interest Purchase Agreement Liability [Table Text Block]
Schedule of royalty purchase agreement
Schedule of Maturities of Long-Term Debt [Table Text Block]
Schedule of amount of principal payments due
Schedule of Segment Reporting Information, by Segment [Table Text Block]
Schedule of significant expense categories regularly reviewed by the CODM
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]
Schedule of calculation of diluted net loss per share
Business Combination, Separately Recognized Transactions [Table]
Business Combination, Separately Recognized Transactions [Line Items]
Organization and Basis of Presentation
Defined Benefit Plan, Plan Assets, Allocation [Table]
Defined Benefit Plan, Plan Assets, Allocation [Line Items]
Summary of Significant Accounting Policies
Accounts Receivable, Allowance for Credit Loss, Current
Allowance for doubtful accounts receivable
Inventory Valuation Reserves
Inventory impairment charge
Impairment, Long-Lived Asset, Held-for-Use
Impairment of long-lived assets
Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay
Defined contribution plan, percentage
Defined Contribution Plan, Cost
Contribution
Number of Reportable Segments
Property, Plant and Equipment [Table]
Long-Lived Tangible Asset [Axis]
Long-Lived Tangible Asset [Domain]
Manufacturing Equipment
Manufacturing equipment
Office Equipment [Member]
Office furniture
Office equipment
Research And Development Equipment
Research and development equipment
Statistical Measurement [Axis]
Statistical Measurement [Domain]
Minimum [Member]
Minimum
Maximum [Member]
Maximum
Property, Plant and Equipment [Line Items]
Schedule of Property and Equipment, Net
Property, Plant and Equipment, Useful Life
Total asset category
Medtronic Agreement (Details) [Table]
Statement of Financial Position Location, Activity, Accrual [Axis]
Statement of Financial Position Location, Activity, Accrual [Domain]
Accounts Payable and Accrued Liabilities [Member]
Accounts Payable and Accrued Expenses
Counterparty Name [Axis]
Counterparty Name [Domain]
Represents the information pertaining to Medtronic, Inc.
Medtronic, Inc [Member]
Medtronic, Inc.
Debt Instrument [Axis]
Debt Instrument, Name [Domain]
Represents information pertaining to Loan Agreement (the "Loan Agreement") with Medtronic, pursuant to which Medtronic agreed to extend a convertible loan to the Company.
Convertible Loan Agreement [Member]
Loan Agreement
Long-Term Debt, Type [Axis]
Long-Term Debt, Type [Domain]
Represents the information pertaining to secured subordinated convertible promissory note.
Secured Subordinated Convertible Promissory Note [Member]
Secured Subordinated Convertible Promissory Note (the "Notes")
Sale of Stock [Axis]
Sale of Stock [Domain]
Represents information pertaining to Series D-2 preferred stock.
Series D-2 Preferred Stock [Member]
Series D-2 Preferred Stock
Private Placement [Member]
Private Placement
Over-Allotment Option [Member]
Public Offering
Related and Nonrelated Parties [Axis]
Related and Nonrelated Parties [Domain]
Related Party [Member]
Related Party
Medtronic Agreement (Details) [Line Items]
Medtronic Agreement
Expected revenue amount per unit.
Estimated Future Product Price
Expected to receive product price
The amount of reimbursable research and development expense.
Reimbursable Research And Development Expense
Reimbursable research and development expense
Proceeds from Issuance or Sale of Equity
Proceeds from issuance of Series D-2 Preferred Stock
Debt Instrument, Face Amount
Term loan
Shares Issued, Price Per Share
Share issue price (in dollars per share)
Maximum number of additional shares to be purchase if the option is exercised.
Sale Of Stock, Maximum Additional Shares Issuable Upon Exercise Of Option
Additional shares to be purchased
The amount of revenue recognized to date under agreement.
Revenue Recognized To Date
Revenue recognized to date
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]
Fair Value Hierarchy and NAV [Axis]
Fair Value Hierarchy and NAV [Domain]
Fair Value, Inputs, Level 1 [Member]
Level 1
Fair Value, Inputs, Level 2 [Member]
Level 2
Fair Value, Inputs, Level 3 [Member]
Level 3
Financial Instrument [Axis]
Financial Instruments [Domain]
Money Market Funds [Member]
Money market fund (included in Cash and cash equivalents)
Corporate Debt Securities [Member]
Corporate debt Securities
Corporate and government debt securities (included in Marketable securities)
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Financial Instruments and Fair Value Measurements
Assets, Fair Value Disclosure
Total assets
Liabilities, Fair Value Disclosure
Total liabilities
Assets transfers within levels
Assets Transfers Within Levels
Assets transfers within levels
Liabilities transfers within levels
Liabilities Transfers Within Levels
Liabilities transfers within levels
Marketable Securities [Table]
US Government Debt Securities [Member]
Government debt securities
Marketable Securities [Line Items]
Marketable Securities
Debt Securities, Available-for-Sale, Amortized Cost, after Allowance for Credit Loss
Amortized Cost Basis
Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax
Unrealized Gains
Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax
Unrealized Losses
Debt Securities, Available-for-Sale
Fair Value
Strategic Investment Motus GI
Strategic investments Motus GI
strategic Investment Vivasure Member
Strategic Investment Vivasure
Debt Securities, Available-for-Sale, Realized Gain
Realized gains
Debt Securities, Available-for-Sale, Realized Loss
Realized losses
Asset Impairment Charges
Impairment charge
Amount of consideration receivable on sale of investment in equity security without readily determinable fair value.
Consideration Receivable Equity Securities Without Readily Determinable Fair Value
Consideration receivable equity securities
Amount of initial upfront payment received on sale of investment in equity security without readily determinable fair value.
Initial Upfront Payment, Sale Of Equity Securities Without Readily Determinable Fair Value
Initial upfront payment
Debt Securities, Available-for-Sale, Noncurrent
Debt securities with maturities between 12 and 36 months
The amount of Property plant and equipment not placed in service yet and has not commenced depreciation as on date.
Property Plant and Equipment, Not Placed In Service
Property plant and equipment not placed in service yet and has not commenced
Equipment [Member]
Equipment
Leaseholds and Leasehold Improvements [Member]
Leasehold improvements
Property, Plant and Equipment, Gross
Property and equipment, gross
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment
Less accumulated depreciation and amortization
Clinical Trial Accruals
Clinical trial accruals
Employee-related Liabilities, Current
Accrued compensation
Other Accrued Liabilities, Current
Other accrued expenses
Stock, Class of Stock [Table]
Represents information pertaining to terumo securities purchase agreement.
Terumo Securities Purchase Agreement [Member]
Terumo securities purchase agreement
Class of Stock [Line Items]
Common and Preferred Stock
Common Stock, Number of Shares, Par Value and Other Disclosure [Abstract]
Common Stock
Preferred Stock, Number of Shares, Par Value and Other Disclosure [Abstract]
Preferred Stock
Preferred Stock, Shares Outstanding
Preference shares, shares outstanding
Number of new stock classified as temporary equity issued during the period.
Temporary Equity, Stock Issued During Period, Shares, New Issues
Issuance of Series A Preferred Stock (in shares)
Per share or per unit amount of temporary equity issued.
Temporary Equity Issued, Price Per Share
Series A redeemable preferred stock, issue price
The gross inflow from issuance of callable preferred stock which is identified as being convertible to another type of financial security at the option of the issuer or the holder.
Proceeds From Issuance Of Convertible Preferred Stock, Gross
Series A preferred stock, gross proceeds
Increase (Decrease) in Temporary Equity [Roll Forward]
Increase (Decrease) in Mezzanine Equity
Amount of adjustment to carrying value of Series A Preferred Stock
Temporary Equity, Adjustment to Carrying Value of Series A Preferred Stock
Adjustment to carrying value of Series A Preferred Stock
Represents information pertaining to 2024 ATM agreement.
At-The-Market Offering 2024 [Member]
At-the-Market offering
Represents the member information pertaining to sales agreement.
Sales Agreement [Member]
Sales agreement
Aggregate amount of common shares reserved for future issuance.
Common Stock, Capital Reserved for Future Issuance
Aggregate offering price of common stock
Proceeds from Issuance of Common Stock
Aggregate gross proceeds from common stock
The amount represents the common stock reserved for future issuance.
Common Stock Reserved for Future Issuance
Common stock reserved for future issuance
A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.
Increase (Decrease) In Embedded Derivative Liability [Roll Forward]
Increase (Decrease) In Derivative Liability
Fair Value Measurement Inputs and Valuation Techniques [Table]
Measurement Input Type [Axis]
Measurement Input Type [Domain]
Measurement Input, Expected Term [Member]
Expected term (in years)
Measurement Input, Price Volatility [Member]
Expected volatility
Measurement Input, Risk Free Interest Rate [Member]
Risk-free interest rate
Measurement Input, Expected Dividend Rate [Member]
Expected dividend yield
Measurement Input, Discount for Lack of Marketability [Member]
Market discount rate
Measurement Input, Share Price [Member]
Fair value of common stock
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Assumptions for derivative components
Embedded Derivative Liability, Measurement Input
Embedded derivative liability, measurement input
Class of Warrant or Right [Table]
Class of Warrant or Right [Axis]
Class of Warrant or Right [Domain]
Represents information relating to Equity-classified Warrants.
Equity-classified Warrants
Equity-classified Warrants
Represents information pertaining to prefunded warrants.
Prefunded Warrants [Member]
Pre-Funded Warrants
Represents the information pertaining to Ligand Warrants.
Ligand Warrants [Member]
Ligand Warrant
Represents information relating to Legacy Orchestra Equity classified Warrants.
Legacy Orchestra Warrants.
Legacy Orchestra Warrants
Represents information relating to Hercules Warrants.
Equity Classified Hercules Warrants [Member]
Hercules Warrants
Represents information relating to Avenue Warrants.
Avenue Warrants
Avenue Warrants
Represents information relating to Non-employee Warrants.
Equity Classified Non Employees Warrants [Member]
Non-employee Warrants
Represents information pertaining to Private Warrants Held By Sponsor.
Private Warrants Held by Sponsor
Private Warrants Held by Sponsor
Represents information pertaining to Officer and Director warrants.
Officer And Director Warrants
Class of Warrant or Right [Line Items]
Warrants
Class of Warrant or Right, Outstanding
Warrants
Class of Warrant or Right, Exercise Price of Warrants or Rights
Price per share (in dollars per share)
Exercise Price
Warrants and Rights Outstanding, Term
Warrants expiry term
Term
The issue price of warrants or rights outstanding during the period.
Warrants or Rights Outstanding, Issue Price
Price of warrants or rights outstanding
Proceeds from Issuance of Warrants
Issuances of warrants
Nominal exercise price per share or per unit of warrants or rights outstanding.
Class of Warrant or Right, Nominal Exercise Price of Warrants or Rights
Exercise price of warrants or rights
Number of warrants issued during the period.
Class Of Warrant Or Right Number Of Warrants Issued
Number of warrants issued
Number of warrants or rights forfeited during the period.
Class Of Warrant Or Right, Forfeited
Number of warrants forfeited
Number of specified employees and directors who received the newly issued warrants.
Number Of Specified Employees And Directors, Warrants Issued
Number of specified employees and directors warrants issued
Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]
Plan Name [Axis]
Plan Name [Domain]
Represents the information pertaining to 2023 Equity Incentive Plan.
2023 Plan
2023 Plan
Represents information pertaining to new hire inducement plan.
New Hire Inducement Plan [Member]
New Hire Inducement Plan
Legal Entity [Axis]
All Entities [Member]
Represents the information pertaining to Orchestra BioMed, Inc.
Legacy Orchestra
Legacy Orchestra
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Stock-Based Compensation
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized
Number of shares authorized
Represents the number of employees to whom the an award under share-based payment arrangement is granted.
Share-Based Compensation Arrangement By Share Based Payment Award, Number Of Employees
Number of new employees to whom inducement equity awards granted
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross
Shares Underlying Options, Granted
Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period
Expiration period (in years)
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period
Vesting period (in years)
Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Outstanding Stock Maximum
Percentage of shares outstanding
Common Stock, Capital Shares Reserved for Future Issuance
Shares available for future issuance
The number of shares into which fully or partially vested warrants outstanding as of the balance sheet date can be currently converted.
Class Of Warrant Or Right, Exercisable
Warrants exercisable
Period over which grantee's right to exercise warrant is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.
Class of Warrant or Right, Vesting Period
Warrants vesting period
Warrants and Rights Outstanding, Measurement Input
Warrants, measurement input
Stock options
Restricted Stock [Member]
Restricted Stock
Unvested restricted stock units
Warrant [Member]
Warrant
Company common stock warrants
Statement of Income Location, Balance [Axis]
Statement of Income Location, Balance [Domain]
Research and Development Expense [Member]
Research and development
Selling, General and Administrative Expenses [Member]
Selling, general and administrative
Share-Based Payment Arrangement, Expense
Total stock-based compensation
Stock-based compensation
Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount
Unrecognized stock-based compensation expense for options
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition
Expected period to be recognized
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]
Shares Underlying Options
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number
Shares Underlying Options, Ending
Shares Underlying Options, Beginning
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period
Shares Underlying Options, Forfeited/canceled
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number
Shares Underlying Options, Exercisable
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]
Weighted Average Exercise Price
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price
Weighted Average Exercise Price Outstanding, Ending
Weighted Average Exercise Price Outstanding, Beginning
Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
Weighted Average Exercise Price, Granted
Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price
Weighted Average Exercise Price, Exercised
Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price
Weighted Average Exercise Price, Forfeited/canceled
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price
Weighted Average Exercise Price, Exercisable
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]
Weighted Average Remaining Term (years) and Aggregate Intrinsic Value
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term
Weighted Average Remaining Term (years), Outstanding
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term
Weighted Average Remaining Term (years), Exercisable
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value
Aggregate Intrinsic Value Outstanding
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value
Aggregate Intrinsic Value, Exercised
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value
Aggregate Intrinsic Value, Exercisable
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value
Weighted average grant date fair value
Represents the information pertaining to performance based restricted stock awards.
Performance Based Restricted Stock Awards [Member]
Performance-Based Restricted Stock Awards
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Restricted Stock Outstanding
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number
Restricted stock, Ending
Restricted stock, Beginning
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period
Restricted stock, Granted
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period
Restricted stock, Vested
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]
Weighted Average Grant Date Fair Value
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value
Weighted Average Grant Date Fair Value, Ending
Weighted Average Grant Date Fair Value, Beginning
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value
Weighted Average Grant Date Fair Value, Granted
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value
Weighted Average Grant Date Fair Value, Vested
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested
Aggregate Intrinsic Value, Vested
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term
Expected term
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate
Expected volatility
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate
Risk-free interest rate
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate
Expected dividend yield
Share Price
Fair value of common stock
Leases (Details) [Table]
Leases (Details) [Line Items]
Leases
Area of Real Estate Property
Lease space
Operating Lease, Cost
Rent lease expense
Fixed operating expense
Short-Term Lease, Cost
Short term lease expense
Short-term lease expense
Variable Lease, Cost
Variable lease costs
Variable lease expense
The monthly amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.
Monthly Lease And Rental Expense
Monthly rent expense
Operating Lease, Payments
Cash paid for operating lease liabilities
Operating Lease, Weighted Average Remaining Lease Term
Weighted average remaining lease term - operating leases, in years
Operating Lease, Weighted Average Discount Rate, Percent
Weighted average discount rate - operating leases
Lease, Cost
Total lease expense
Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]
Operating Lease Maturity
Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year
2026 (remaining nine months)
Lessee, Operating Lease, Liability, to be Paid, Year One
2027
Lessee, Operating Lease, Liability, to be Paid, Year Two
2028
Lessee, Operating Lease, Liability, to be Paid, Year Three
2029
Lessee, Operating Lease, Liability, to be Paid, Year Four
2030
Amount of lessee's undiscounted obligation for lease payment for operating lease due after fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).
Lessee Operating Lease Liability Payments Due After Year Four
Thereafter
Lessee, Operating Lease, Liability, to be Paid
Total future minimum lease payments
Lessee, Operating Lease, Liability, Undiscounted Excess Amount
Imputed interest
Operating Lease, Liability
Total liability
Related Party Transaction [Table]
Represents the information pertaining to entities associated with RTW Investments, LP (collectively, "RTW").
Entities Associated with RTW Investments, LP [Member]
Entities associated with RTW Investments, LP
Represents the information pertaining to Perceptive Life Sciences Master Fund, Ltd.
Perceptive Life Sciences Master Fund, Ltd [Member]
Perceptive Life Sciences Master Fund, Ltd
Related Party Transaction [Line Items]
Related Party Transactions
Equity Ownership, Excluding Consolidated Entity and Equity Method Investee, Percentage
Percentage of beneficially owned equity ownership
Disclosure of information about Revenue interest purchase agreement.
Revenue Interest Purchase Agreements (Details) [Table]
Represents the information pertaining to Ligand Pharmaceuticals Incorporated.
Ligand Pharmaceuticals Incorporated [Member]
Ligand Pharmaceuticals Incorporated (the "Purchaser")
Collaborative Arrangement and Arrangement Other than Collaborative [Axis]
Collaborative Arrangement and Arrangement Other than Collaborative [Domain]
Represents the information pertaining to Revenue Participation Right Purchase and Sale Agreement.
Revenue Participation Right Purchase and Sale Agreement [Member]
Revenue Participation Right Purchase and Sale Agreement
Represents the information pertaining to Ligand Stock Purchase Agreement pursuant to Revenue Participation Right Purchase and Sale Agreement.
Ligand Stock Purchase Agreement [Member]
Ligand Stock Purchase Agreement
Represents the information pertaining to products of company being (s) AVIM therapy (the "Primary Product") and (b) Virtue SAB (the "Secondary Product" and together with the Primary Product, the "Products") in the field of coronary artery treatment.
AVIM Therapy and Virtue Sab Products [Member]
AVIM Therapy and Virtue Sab Products ("Products")
Represents information pertaining to AVIM Therapy products
Avim Therapy Products [Member]
Avim Therapy Products
Represents information pertaining to Virtue SAB products.
Virtue Sab Products [Member]
Virtue Sab Products
Vesting [Axis]
Vesting [Domain]
Represents the information pertaining to Tranche one.
Tranche One Payment [Member]
Tranche One
Represents the information pertaining to Tranche two.
Tranche Two Payment [Member]
Tranche Two
Scenario [Axis]
Scenario [Domain]
Represents the information pertaining to a scenario where the annual net sales of the products are less than or equal to $100 million.
Annual Net Sales Less Than Or Equal To 100 Million [Member]
Annual Net Sales of the products are less than or equal to $100 million
Represents the information pertaining to a scenario where the annual net sales of the products are greater than or equal to $100 million.
Annual Net Sales Greater Than Or Equal To 100 Million [Member]
Annual Net Sales of the products are greater than or equal to $100 million
Represents information pertaining to royalty rate applicable until second installment is paid.
Royalty Rate Applicable Until Second Installment Is Paid [Member]
Royalty Rate Applicable Until Second Installment Is Paid
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
Revenue Interest Purchase Agreements (Details) [Line Items]
Royalty Purchase Agreement
Amount of consideration receivable in pursuant to the sale of future revenue interest.
Consideration Receivable From Sale Of Future Revenues Interests
Investment amount
Number of tranches in which investment amount shall be paid.
Number Of Tranches
Number of tranches
The amount of cash inflow from Revenue interest purchase agreement entered .
Proceeds From Revenue Interest Purchase agreement
Proceeds from the royalty purchase agreement
The percentage of revenues remitted related to products until threshold limit.
Revenue Payment, Initial Prepayment rate
Percentage of revenue repayment
The amount of threshold for revenue repayments during the period.
Revenue Repayment Threshold Amount Monetary Duration Debit
Amount of revenue repayment
The percentage of revenues remitted related to products after threshold limit.
Revenue Payment, Prepayment rate Post Threshold Amount
Threshold amount of revenue repayment
Percentage of royalty that is paid on the funded amount as per the agreement.
Royalty Rate On Funded Amount
Percentage of royalty funded amount as per the agreement
Percentage of revenue sharing being a Applicable Purchaser Revenue Interest Rate.
Revenue Sharing Percentage, Applicable Purchaser Revenue Interest Rate
Revenue sharing percentage (%)
Class of Warrant or Right, Number of Securities Called by Warrants or Rights
Number of warrants to be issued
Debt Instrument, Interest Rate, Effective Percentage
Interest rate
Amount of interest expense added to liability related to Revenue Interest Purchase Agreement.
Revenue Interest Purchase Agreement Liability, Interest Additions
Non-cash interest expense on liability
Schedule of Long-Term Debt Instruments [Table]
Represents information pertaining to Medtronic.
Medtronic [Member]
Medtronic
Represents the scenario if prepayment occurs within 12 months of the agreement closing date.
If Prepayment Occurs Within 12 Months of the Agreement Closing Date [Member]
Prepayment within 12 months of agreement closing date
Represents the scenario if prepayment occurs after 12 months and within 24 months of the agreement closing date.
If Prepayment Occurs After 12 Months And Within 24 Months of the Agreement Closing Date [Member]
Prepayment after 12 months but within 24 months of agreement closing date
Represents the scenario if prepayment occurs after 24 months of the agreement closing date.
If Prepayment Occurs After 24 Months of the Agreement Closing Date [Member]
Prepayment after 24 months of agreement closing date
Represents the information pertaining to scenario where FDA approve a Medtronic device incorporating AVIM is achieved prior to the Repayment Date.
FDA Approval Of Medtronic AVIM Device Prior To Repayment Date [Member]
FDA approval of a Medtronic device incorporating AVIM is achieved prior to the Repayment Date
Represents the information pertaining to 2024 Loan and Security Agreement.
Two Thousand Twenty Four Loan And Security Agreement [Member]
2024 Loan and Security Agreement
Represents the information pertaining to Tranche one of 2024 Loan and Security Agreement.
Two Thousand Twenty Four Loan And Security Agreement Tranche One [Member]
Tranche one loan and security agreement
Represents the information pertaining to Tranche two of 2024 Loan and Security Agreement.
Two Thousand Twenty Four Loan And Security Agreement Tranche Two [Member]
Tranche two loan and security agreement
Debt Instrument [Line Items]
Debt Financing
Debt Instrument, Basis Spread on Variable Rate
Interest rate variable (as a percent)
Debt Instrument, Variable Interest Rate, Type [Extensible Enumeration]
Debt Instrument, Interest Rate, Stated Percentage
Interest rate stated (as a percent)
Debt Instrument, Term
Repayment terms of the loan
Represents the number of monthly principal plus interest payments.
Number Of Monthly Principal Plus Interest Payments
Number of principal plus interest payments
Represents the percentage of prepayment premium if all or a portion of debt is prepaid.
Debt Instrument, Prepayment Premium
Prepayment premium
Percentage of prepayment rate to be paid as an end of term charge upon prepayment or repayment of the term loans.
Debt Instrument, Prepayment Charge, Percentage
End of term charge (in percent)
Percentage of facility rate to be paid upon any draw of the term loans.
Debt Instrument, Facility Charge, Percentage
Facility charge (in percent)
Represents the multiplier factor used to calculate common stock.
Debt Instrument, Multiplier Factor Used to Calculate Common Stock
Multiplier factor used to calculate common stock
Percentage of debt instrument cash coverage.
Debt Instrument Cash Coverage Percentage
Cash coverage percentage
Debt Instrument, Maturity Date
Maturing or Repayment date of the Note
Percentage of revenue share amounts to be paid in exchange for extinguishment of debt.
Debt Extinguishment, Percentage Of Revenue Share Amount
Debt extinguishment, percentage of revenue share amount (%)
Amount of revenue share credit payment under "Collaboration Agreement".
Debt Extinguishment, Revenue Share Amount
Debt extinguishment, Revenue Share Credit payments
Percentage of additional default interest rate in the event of default.
Debt Instrument, Additional Default Interest Rate
Additional debt default interest rate (%)
Interest Expense, Debt
Interest expense
Long-Term Debt, Fiscal Year Maturity [Abstract]
Debt Maturity
Long-Term Debt, Maturity, Remainder of Fiscal Year
2026 (remaining nine months)
Long-Term Debt, Maturity, Year One
2027
Long-Term Debt, Maturity, Year Two
2028
Long-Term Debt, Maturity, Year Three
2029
Long-Term Debt
Total
Schedule of Segment Reporting Information, by Segment [Table]
Segments [Axis]
Segments [Domain]
Represents information pertaining to single reportable segment.
Single Reportable Segment [Member]
Single Reportable Segment
Represents information pertaining to non-clinical development costs.
Non-Clinical Development Costs [Member]
Non-clinical development costs
Represents information pertaining to clinical development costs.
Clinical Development Costs [Member]
Clinical development costs
Segment Reporting Information [Line Items]
Segment Disclosures
Represents the amount of development costs.
Development Expenses
Development costs
Labor and Related Expense
Personnel and consulting costs
Segment Reporting, Other Segment Item, Amount
Other segment expenses
Segment Reporting, Other Segment Item, Composition, Description
Schedule of Business Acquisitions, by Acquisition [Table]
Represents information pertaining to HSAC 2 Holdings, LLC.
HSAC 2 Holdings, LLC
HSAC 2 Holdings, LLC
Represents information pertaining to Health Sciences Acquisitions Corporation 2.
HSAC2
HSAC2
Represents the scenario of initial milestone event.
Initial milestone event
Initial Milestone Event
Represents the scenario of final milestone event.
Final milestone event
Final Milestone Event
Business Acquisition [Line Items]
Net Loss Per Share
Percent of shares forfeited by the sponsor.
Sponsor, Shares Forfeiture, Percent
Sponsor share forfeiture (as percent)
Number of shares forfeited by the sponsor.
Sponsor, Shares Forfeiture, Number
Number of shares forfeiture by sponsor
Price of the entity's common stock which would be required to be attained for the forfeiture of sponsor shares to become effective.
Sponsor, Shares Forfeiture, Stock Price Trigger
Sponsor share forfeiture, stock price trigger
Threshold number of specified trading days that common stock price must exceed threshold percentage within a specified consecutive trading period to trigger forfeiture of sponsor shares.
Sponsor, Shares Forfeiture, Threshold Trading Days
Sponsor share forfeiture, threshold trading days
Threshold period of specified consecutive trading days within which common stock price must exceed threshold percentage for specified number of trading days to trigger forfeiture of sponsor shares.
Sponsor, Shares Forfeiture, Threshold Consecutive Trading Days
Sponsor share forfeiture, threshold consecutive trading days
Number of shares of equity interests issued or issuable as earnout consideration in a business combination.
Business Acquisition, Earnout Consideration, Equity Interest Issued or Issuable, Number of Shares
Number of shares issuable as earnout consideration
The lock up period of shares.
Shares Lock Up Period
Share lock up period
Percent of shareholders elected to participate in earnout.
Percent of Shareholders Elected to Participate in Earnout
Percent of shareholders elected to participate in earnout
The number of shares of equity interests issued as earn-out consideration in a business combination, after rounding.
Business Acquisition, Earn-out Consideration, Equity Interests, Number of Shares Issued After Rounding
Number of shares issuable as earnout consideration due to rounding
Incremental Common Shares Attributable to Dilutive Effect of Nonvested Shares with Forfeitable Dividends
Forfeitable shares
Antidilutive Security, Excluded EPS Calculation [Table]
Antidilutive Securities [Axis]
Antidilutive Securities, Name [Domain]
Convertible Preferred Stock [Member]
Convertible Preferred Stock
Series A Preferred Stock
Represents forfeitable shares.
Forfeitable Shares
Forfeitable shares
Represents earnout consideration.
Earnout Consideration
Earnout consideration
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive Securities
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
Antidilutive securities